What changed from existing technology?
This study shows that a group of important proteins work together to control the activity of a special DNA region that turns on a gene called LGR5 in bowel cancer. This gene is important for cancer cells to grow and spread.
This study identifies a specific regulatory circuit involving MYC, ETS2, and FOXP1 that controls super-enhancer activity in colorectal cancer, which was not previously understood.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 0
- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
- 장기·실사용 검증 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Early research
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
This discovery could help in developing targeted therapies for colorectal cancer by understanding how LGR5 is activated through this regulatory circuit.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.